Akèy › Timè nan sèvo › Oregon
Etid klinik pou Timè nan sèvo nan Oregon
8 etid pou Timè nan sèvo ap chèche patisipan nan sit nan Oregon.
Vil nan Oregon
Tèks ofisyèl etid la (Anglè)
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- Saint Alphonsus Medical Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- ak 8 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04511013Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
- OHSU Knight Cancer Institute, Portland
Ap rekriteFaz 2
Laj 10 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT03270059A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Providence Cancer Institute, Portland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871An Exercise Intervention for Improving Mental and Physical Health in Patients With Primary Brain Tumors and Their Caregivers, ET-NEURO Trial
- OHSU Knight Cancer Institute, Portland
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07278440Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
- Oregon Health & Science University, Portland
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Aug 19, 2026 · NCT05317858Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- Legacy Good Samaritan Hospital and Medical Center, Portland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 9, 2026 · NCT03550391cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Kaiser Permanente Northwest, Portland
- Oregon Health and Science University, Portland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 8, 2025 · NCT03418961Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.